Psychometric Properties of the Patient-Reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life (PROMPT-QOL)
Overview
Authors
Affiliations
Objectives: To assess the psychometric properties of a novel instrument for medication management, the Patient-Reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life (PROMPT-QOL), using both conventional psychometrics and Rasch analysis in a large sample.
Methods: This study was conducted with 1156 adult outpatients continuously taking any medicines at least 3 months from three university hospitals in Bangkok, Thailand, between July 2014 and March 2015. The psychometric properties were assessed in five steps: 1) assessment of dimensional structure, 2) item selection, 3) assessment of practicality, 4) assessment of reliability, and 5) assessment of criterion and known-groups validity.
Results: The PROMPT-QOL contained 43 items including nine domains, and their five-point Likert scale functioning worked well. Most items fulfilled the item selection criteria. The PROMPT-QOL took an average administration time of 13.4 ± 5.8 minutes. Only two items had missing data of 0.1% to 0.2%. All domains provided good to excellent test-retest reliability with intraclass correlation coefficients between 0.67 and 0.83. All domains of the PROMPT-QOL yielded high Cronbach's α values between 0.77 and 0.89, greater than an acceptable level of 0.70, except for the Availability and Accessibility domain (0.58). A multiple regression showed that the Medication Effectiveness domain was the strongest predictor of the overall QOL of the PROMPT-QOL, followed by the Therapeutic Relationships, Psychological Impacts, Convenience, and Availability and Accessibility domains (adjusted R ~ 52%). As expected, patients with higher PROMPT-QOL domain scores were associated with being younger, more educated, having a lower number of medicines, patients' perceptions of better disease control, having no adverse drug reactions, and medicine preference.
Conclusions: The PROMPT-QOL was practical, reliable, and valid for Thai patients.
Al-Ebrahim S, Hafidh K, Jallo M, Mauwfak M, Nassef M, Alzubaidi H Explor Res Clin Soc Pharm. 2025; 17:100568.
PMID: 39926417 PMC: 11803884. DOI: 10.1016/j.rcsop.2025.100568.
Al-Ebrahim S, Harrison J, Chen T, Alzubaidi H, Mohammed M Explor Res Clin Soc Pharm. 2024; 16:100523.
PMID: 39498226 PMC: 11532770. DOI: 10.1016/j.rcsop.2024.100523.
Measuring Quality of Life in Deprescribing Trials: A Scoping Review.
Thompson W, Lundby C, Bleik A, Waring H, Hong J, Xi C Drugs Aging. 2024; 41(5):379-397.
PMID: 38709466 DOI: 10.1007/s40266-024-01113-0.
Medication-Related Quality of Life in Thai Epilepsy Patients.
Sakthong P, Suriyapakorn B J Epilepsy Res. 2020; 9(2):139-146.
PMID: 32509550 PMC: 7251341. DOI: 10.14581/jer.19016.
Pharmacotherapy related quality of life in Thai patients with chronic diseases.
Sakthong P Int J Clin Pharm. 2019; 41(4):1004-1011.
PMID: 31168762 DOI: 10.1007/s11096-019-00857-9.